PATENT CLAIM ANALYSIS

Application Number: 16127498
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "250000"]

Abstract:
A method for inhibiting a lipid metabolism disorder of a warm-blooded animal includes administering a therapeutically effective amount of a compound being one selected from the group consisting of phosphodiesterase 5 (PDE-5) inhibitors of the first type and second type and a Statin analogue to a warm-blooded animal suffering from the lipid metabolism disorder. The method may treat the disease selected from the group consisting of liver disease, non-alcoholic fatty liver disease, hyperadiposity, dyslipidemia, hepatic steaotosis, high-fat-diet-induced lipid accumulation, high-fat-diet-induced obesity, insulin resistance, high-fat-diet-induced lipid accumulation combined with a symptom of one of inflammation and liver damage, and any combination thereof.

Claim (Index 6):
A method for inhibiting a lipid metabolism disorder, wherein the lipid metabolism disorder is one selected from the group consisting of non-alcoholic fatty liver disease, hyperadiposity, dyslipidemia, hepatic steaotosis, high-fat-diet-induced lipid accumulation, insulin resistance, high-fat-diet-induced lipid accumulation combined with a symptom of one of inflammation and liver damage, and any combination thereof, the method comprising:\n providing a warm-blooded animal suffering from the disease; and administering a pharmaceutically effective amount of a pharmaceutical combination of a compound and a Statin analogue to the warm-blooded animal, wherein the compound is one of Sildenafil analogue and Sildenafil analogue-RX compound, wherein RX includes a carboxylic group selected from the group consisting of D-ascorbic acid, L-ascorbic acid, DL-ascorbic acid, oleic acid, phosphoric acid, citric acid, nicotinic acid, sodium carboxymethylcellulose (sodium CMC), hyaluronic acid, polyacrylic acid (PAA), polymethacrylates (PMMA), Eudragit, dextran sulfate, heparan sulfate, polylactic acid or polylactide (PLA), polylactic acid sodium (PLA sodium), polyglycolic acid sodium (PGCA sodium), poly-\u03b3-polyglutamic acid sodium (\u03b3-PGA sodium), \u03b3-polyglutamic acid (\u03b3-PGA), alginate-poly-l-lysine-alginate (APA) and poly-\u03b3-polyglutamic acid derivative.

Metadata:
- Claim Count in Document: 15.0
- Percentile: 97.0
- Lexical Diversity: 1.78125
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13044899', '15715702', '14843873', '11916356', '15891324']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6838611882860568
- 35 USC 102 Novelty (BERT): 0.473662906298728
- Combined Prediction Score: 0.662841360087324
- Mean Citation Score: 156.64038599999995
- Max Citation Score: 182.25172
- Similarity Product: 142.18150607033968

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test